Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Scully M, de la Rubia J, Pavenski K, Metjian A, Knöbl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Scully M, et al. Among authors: cataland s. J Thromb Haemost. 2022 Dec;20(12):2810-2822. doi: 10.1111/jth.15892. Epub 2022 Oct 21. J Thromb Haemost. 2022. PMID: 36138517 Free PMC article. Clinical Trial.
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Cataland SR, et al. Am J Hematol. 2012 Apr;87(4):430-2. doi: 10.1002/ajh.23106. Epub 2012 Feb 24. Am J Hematol. 2012. PMID: 22367751 Free article. Clinical Trial. No abstract available.
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Peyvandi F, et al. Among authors: cataland s. N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Free article. Clinical Trial.
Thrombotic thrombocytopenic pupura (TTP) dinner symposium proceedings.
Pavenski K, Cataland S, Kremer Hovinga J, Thomas M, Vanhoorelbeke K. Pavenski K, et al. Among authors: cataland s. Expert Rev Hematol. 2016 Aug;9(8):733-5. doi: 10.1080/17474086.2016.1198895. Epub 2016 Jun 22. Expert Rev Hematol. 2016. PMID: 27269186
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Scully M, et al. Among authors: cataland s. J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30. J Thromb Haemost. 2017. PMID: 27868334 Free article.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK. Peyvandi F, et al. Among authors: cataland s. J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5. J Thromb Haemost. 2017. PMID: 28445600 Free article. Clinical Trial.
Novel therapies in thrombotic thrombocytopenic purpura.
Masias C, Cataland SR. Masias C, et al. Res Pract Thromb Haemost. 2017 Dec 18;2(1):19-26. doi: 10.1002/rth2.12066. eCollection 2018 Jan. Res Pract Thromb Haemost. 2017. PMID: 30046703 Free PMC article.
201 results